

Press Release

For immediate release

Coriolis Pharma appoints Johannes Clemens as new Head of Business Development

Johannes Clemens will be responsible for expanding Coriolis' worldwide activities and services, including client business and the establishment of new collaborative partnerships.

Martinsried-Munich, Germany, September 4, 2023 – Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines, today announced the appointment of Johannes Clemens as its new Head of Business Development. In this role, Johannes Clemens will report to Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma.

Prior to joining Coriolis on August 15, 2023, Clemens was responsible for global business development at Vetter Pharma, a global CDMO since 2010. He grew the global Late Stage and commercial business by establishing new clients and collaborative partnerships and drove the development and launch of new products and services. Johannes started his professional journey as the Managing Director of Smatos, a provider of clinical trial management IT solutions.

Silvia Steyrer-Gruber underscored the significance of Johannes' proficiency accumulated over 15 years as a senior strategist and business developer in the healthcare sector. She remarked, "Johannes' extensive expertise will play a pivotal role in our strategy for global expansion. I am confident that with him, we will significantly drive growth and provide even more exceptional service to our existing and new clients around the world."



Coriolis Pharma has significant expertise in Formulation Research and Development, Analytical Services and non-GMP Manufacturing with innovative high-value biologics. This expertise guarantees clients from the biopharmaceutical industry to create drug products with global commercial potential from the very beginning of the development process.

"Coriolis is ready for the next growth step for its core business and new services," Johannes Clemens expressed. "I am very much looking forward to taking the next steps together with a strong and highly motivated team and writing the future success story for Coriolis."

About Coriolis Pharma

Coriolis Pharma is a globally operating contract research organization and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. The company's offering includes early and late-stage formulation development for liquid and lyophilized drug products, lyophilization process development and analytical development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service portfolio.

It is the vision of Coriolis to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. Coriolis Pharma thereby enables future therapies to be made available to humankind efficiently and on time.

With its interdisciplinary team of highly skilled scientists and an expert scientific advisory board, Coriolis provides cutting-edge services and tailor-made solutions for its clients. Founded in 2008 and headquartered in Martinsried near Munich, Germany, Coriolis currently employs more than 200 employees from over 36 nations around the world.

For more information visit <https://www.coriolis-pharma.com>.

Contact:

Bettina von Klitzing-Stückle
Scientific Marketing Manager
+49 (0) 89 4177 60 – 0
bettina.klitzing@coriolis-pharma.com

Coriolis Pharma Research GmbH
Fraunhoferstr. 18b
82152 Martinsried-Munich
Germany

www.coriolis-pharma.com